Andres-Ejarque, Rosa http://orcid.org/0000-0003-0012-1155
Ale, Hira Bahadur
Grys, Katarzyna
Tosi, Isabella
Solanky, Shane
Ainali, Chrysanthi
Catak, Zeynep
Sreeneebus, Hemawtee
Saklatvala, Jake http://orcid.org/0000-0003-0836-4928
Dand, Nick http://orcid.org/0000-0002-1805-6278
de Rinaldis, Emanuele
Chapman, Anna
Nestle, Frank O.
Barnes, Michael R. http://orcid.org/0000-0001-9097-7381
Warren, Richard B.
Reynolds, Nick J.
Griffiths, Christopher E. M.
Barker, Jonathan N.
Smith, Catherine H.
Di Meglio, Paola http://orcid.org/0000-0002-2066-7780
Di Meglio, Paola
Emsley, Richard
Evans, Andrea
Payne, Katherine
Stocken, Deborah
,
Article History
Received: 19 October 2020
Accepted: 24 June 2021
First Online: 6 August 2021
Change Date: 16 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-27447-6
Competing interests
: The authors declare the following competing interests: C.A. is an employee of DIGNOSIS Ltd. E.d.R. and F.O.N. are currently employees of Sanofi. M.R.B. has received honoraria and/or research grants from Janssen, Servier and Lilly. R.B.W. has received honoraria and/or research grants from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Celgene, Janssen, Leo, Lilly, Novartis, Pfizer, Sanofi, Xenoport, and UCB. N.J.R. has received research grants from GSK-Stiefel and Novartis; and other income to Newcastle University from Almirall, Amgen, Janssen, Novartis, Sanofi Genzyme Regeneron and UCB Pharma Ltd for lectures/attendance at advisory boards. C.E.M.G. reports grants and/or personal fees from AbbVie, Almirall, Amgen, BMS, Celgene, Galderma, Janssen, Leo Pharma, Lilly, Novartis, Sandoz and UCB Pharma. J.N.B. has received honoraria and/or research grants from AbbVie, Almirall, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Celgene, Janssen, Leo, Lilly, Novartis, Samsung, Sun Pharma. C.H.S. has received departmental research funding from AbbVie, GSK, Pfizer, Novartis, Regeneron, and Roche. P.D.M. reports grants and/or personal fees from Janssen, Novartis, and UCB Pharma. All the other authors declare no competing interests.